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Outline
I Introduction to oncology phase I trials
I Describe the original continual reassessment model (CRM)
I How to run the Mata code
I Programming diﬃculties
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Oncology Phase I trials
Want to ﬁnd maximum tolerated dose(MTD) of a novel drug
I The outcome is binary
I A patient has a dose-limiting toxicity or not (e.g. Neutropenia)
I A set of doses are (usually) pre-speciﬁed
I Assume a monotonically increasing relationship between dose
and outcome
I Want to ﬁnd a safe dose that has a certain target probability
of toxicity (TTL)
I If the MTD is d∗ then P(Tox|d∗) = TTL
I the target probability is often between 0.2 and 0.33
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Continual Reassessment Model
This model-based Bayesian method was introduced by J.
O’Quigley Biometrics 1990.
I A working model is speciﬁed for the dose-outcome relationship
I Prior information is required
I Then the study begins by dosing the ﬁrst person at the ”best”
dose
I The analysis is updated given the data obtained
I For the next patient pick the ”best” dose and continue
Sample size generally ﬁxed at the outset (20-30 participants)
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Single-parameter working models
P(d,a) = prob of a Tox at dose d
The following models were suggested in the original paper
I 1-parameter logistic : P(d,a) =
exp(−3+ad)
1+exp(−3+ad)
I power : P(d,a) = p
expa
d
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Implementing the CRM
a is the parameter that is going to be updated during the trial
I exponential prior π(a) = exp(−a) with mean 1







f (x|a)π(a) R ∞
0 f (x|a)π(a)da
Calculate the posterior mean (another integration) and then
substitute this into the model to pick the best dose
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Example from Statistical Methods for Dose-Finding
Experiments
The prior probabilities for each toxicity (”skeleton”) for 6 dose
levels need to be speciﬁed
d1 d2 d3 d4 d5 d6
.04 .07 .2 .35 .55 .7
This is ﬁxed throughout the trial and dictates the shape of the
curve
I TTL is speciﬁed as 0.2
I Default working model is hyperbolic tangent
I Default prior is exponential
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Stata Code
crm y dose, target(0.2) prior(0.04 0.07 0.2 0.35 0.55
0.7)
. l i s t y dose
+ − − − − − − − − − −+
| y dose |
| − − − − − − − − − −|
1. | 0 1 |
2. | 1 3 |
3. | 0 2 |
4. | 0 2 |
5. | 0 2 |
| − − − − − − − − − −|
6. | 1 3 |
7. | 0 2 |
8. | 0 2 |
9. | 0 2 |
10. | 0 2 |
+ − − − − − − − − − −+
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Prior model, but dose the ﬁrst patient at dose level 1
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First person had no tox at dose 1, next patient is given dose 3
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Patient 2 experienced tox at dose 3, next patient is given dose 2
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Patient 2 no tox at dose 2, next patient is given dose 2
Adrian Mander Sep 2011 14/17Outline Phase I
Patient 2 no tox at dose 2, next patient is given dose 2
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Numerical Integration
In order to integrate I had to program up the GaussLaguerre
quadrature (see Wiki).
matrix Ln coef ( real n)
{
f i r s t =1
for ( i =0;i<=n ; i++) {
i f ( f i r s t++==1) coef = (−1)ˆ i∗comb(n , i )/ f a c t o r i a l ( i )
else coef = coef , (−1)ˆ i∗comb(n , i )/ f a c t o r i a l ( i )
}
return ( coef )
}
real integrate0inf ( real fn , real obs , scalar model , dose , y , d , quadpts )
{
roots= sort ( polyroots ( Ln coef ( quadpts )) ’ ,1) ’
for ( i =1;i<=quadpts ; i++) {
i f ( i==1) wt = roots [ i ]/(( quadpts+1)ˆ2∗(Ln( quadpts+1, roots [ i ])ˆ2))
else wt=wt , roots [ i ]/(( quadpts+1)ˆ2∗(Ln( quadpts+1, roots [ i ])ˆ2))
}
integral=0
for ( i =1;i<=quadpts ; i++) {
integral = integral+ wt [ i ]∗ exp ( roots [ i ])∗ f ( fn , obs , roots [ i ] , model , dose , y , d)
}
return ( integral )
}
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Final Thoughts
I Numerical integration could be done at a higher precision (but
not by me!). Perhaps have a mechanism for doing some
calculations at quad-precision?
I Perhaps R has a better integrate function than the one I
wrote?
I To generalise the code it would be good to implement the
following syntax, is this possible?
crm y dose , target (0.2) prior (0.04 0.07 0.2 0.35 0.55 0.7)
model ( xˆexp (a) ) prior ( exp(−2∗a) ) }
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